Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rE-4 in Type 2 Diabetes Mellitus
NCT03239119Phase 3Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Peptides
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03239119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239119.